Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | BUB1 | O43683 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15509063 | 1.00 | CA2 (0.39) | CA2ALDH1A1NPSR1BUB1MAPK14 | |
| SCHEMBL15508939 | 1.00 | CA2 (0.39) | CA2ALDH1A1NPSR1BUB1MAPK14 | |
| SCHEMBL15508951 | 0.81 | CA2 (0.36) | CA2ALDH1A1NPSR1 | |
| SCHEMBL15519467 | 0.81 | CA2 (0.36) | CA2ALDH1A1NPSR1 | |
| SCHEMBL15519213 | 0.76 | CA2 (0.38) | CA2ALDH1A1NPSR1BUB1 | |
| SCHEMBL15509016 | 0.76 | CA2 (0.38) | CA2ALDH1A1NPSR1BUB1 | |
| SCHEMBL1585799 | 0.76 | CA2 (0.41) | CA2ALDH1A1NPSR1BUB1 | |
| SCHEMBL23750730 | 0.75 | CA2 (0.40) | CA2BUB1MAPK14HCRTR1HCRTR2 | |
| SCHEMBL23750637 | 0.75 | CA2 (0.40) | CA2BUB1MAPK14HCRTR1HCRTR2 | |
| SCHEMBL850274 | 0.71 | CA2 (0.43) | CA2ALDH1A1NPSR1BUB1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2909212-B1 | SUBSTITUTED 1,4-DIHYDROPYRAZOLO[4,3-B]INDOLES | TAKEDA PHARMACEUTICALS CO (JP) | 2017-02-22 | — | — | EP | disclosed |
| EP-2909212-B1 | SUBSTITUTED 1,4-DIHYDROPYRAZOLO[4,3-B]INDOLES | TAKEDA PHARMACEUTICALS CO (JP) | 2017-02-22 | — | — | EP | disclosed |
| US-9475816-B2 | Substituted-1,4-dihydropyrazolo[4,3-b]indoles | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-25 | — | — | US | disclosed |
| US-20150225405-A1 | SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225405-A1 | SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES | GPR119, RPLP2, FOXM1 | CA2 3601/4885ALDH1A1 433/4885NPSR1 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.